

CNS Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C236BA812D8AEN.html>

Date: May 2024

Pages: 138

Price: US\$ 6,499.00 (Single User License)

ID: C236BA812D8AEN

Abstracts

The 7 major CNS lymphoma markets are expected to exhibit a CAGR of 3.99% during 2024-2034.

The CNS lymphoma market has been comprehensively analyzed in IMARC's new report titled "CNS Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". CNS (central nervous system) lymphoma refers to a rare type of cancer that affects the lymphatic system in the brain, spinal cord, or other parts of the central nervous system. It originates from lymphocytes, a form of white blood cell that plays a significant role in the body's immune system. The symptoms of this ailment may vary according to the location and size of the tumors. Some common indications associated with the disease include headaches, changes in vision, confusion, memory problems, difficulty speaking or understanding speech, seizures, weakness or numbness in the limbs, hearing loss, nausea, vomiting, increased irritability, etc. The diagnosis of this illness involves a combination of the patient's medical history, clinical features, and physical examination. Numerous imaging tests, such as magnetic resonance imaging and computed tomography scans, are also used to identify abnormalities in the brain or detect the presence of tumors or lesions. The healthcare provider may further perform immunohistochemistry and genetic analysis to determine the specific type and subtype of lymphoma. In some cases, a brain biopsy can be conducted using stereotactic techniques to confirm the diagnosis.

The expanding geriatric population, who are more susceptible to immunosenescence, in which the immune system tends to decline in function, is primarily driving the CNS lymphoma market. Apart from this, the rising incidences of genetic predisposition, causing mutations in tumor suppressor genes that eventually lead to the formation of

cancer, are also creating a positive outlook for the market. Moreover, the widespread adoption of intrathecal chemotherapy, since it involves direct injection of the therapeutic agent in the cerebrospinal fluid using a lumbar puncture to target tumor cells in the CNS, is further bolstering the market growth. Besides this, the inflating application of corticosteroids, such as dexamethasone, to reduce swelling and inflammation in the brain, thereby providing symptom relief and improving overall well-being, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of non-invasive whole-brain radiation therapy for treating patients who have several tumors scattered throughout the brain, as it helps in controlling or slowing down the proliferation of cancerous cells, is expected to drive the CNS lymphoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the CNS lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for CNS lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the CNS lymphoma market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the CNS lymphoma market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the CNS lymphoma market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current CNS lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the CNS lymphoma market performed so far and how will it perform in the

coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the CNS lymphoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the CNS lymphoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of CNS lymphoma across the seven major markets?

What is the number of prevalent cases (2018-2034) of CNS lymphoma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of CNS lymphoma by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with CNS lymphoma across the seven major markets?

What is the size of the CNS lymphoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of CNS lymphoma?

What will be the growth rate of patients across the seven major markets?

CNS Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for CNS lymphoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the CNS lymphoma market?

What are the key regulatory events related to the CNS lymphoma market?

What is the structure of clinical trial landscape by status related to the CNS lymphoma market?

What is the structure of clinical trial landscape by phase related to the CNS lymphoma market?

What is the structure of clinical trial landscape by route of administration related to the CNS lymphoma market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 CNS LYMPHOMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 CNS LYMPHOMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 CNS LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 CNS LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 CNS LYMPHOMA - UNMET NEEDS

10 CNS LYMPHOMA - KEY ENDPOINTS OF TREATMENT

11 CNS LYMPHOMA - MARKETED PRODUCTS

- 11.1 List of CNS Lymphoma Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name - Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 CNS LYMPHOMA - PIPELINE DRUGS

12.1 List of CNS Lymphoma Pipeline Drugs Across the Top 7 Markets

12.1.1 Tirabrutinib - Gilead Sciences/Ono Pharmaceutical

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 Paxalisib - Kazia Therapeutics

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. CNS LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. CNS LYMPHOMA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 CNS LYMPHOMA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 CNS Lymphoma - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 CNS Lymphoma - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

- 15.3.1 CNS Lymphoma - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 CNS Lymphoma - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 CNS Lymphoma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 CNS Lymphoma - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 CNS Lymphoma - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 CNS Lymphoma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 CNS Lymphoma - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 CNS Lymphoma - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 CNS Lymphoma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 CNS Lymphoma - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 CNS Lymphoma - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 CNS Lymphoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 CNS Lymphoma - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 CNS Lymphoma - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 CNS Lymphoma - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 CNS Lymphoma - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 CNS Lymphoma - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 CNS Lymphoma - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 CNS Lymphoma - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 CNS Lymphoma - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 CNS Lymphoma - Access and Reimbursement Overview

16 CNS LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 CNS LYMPHOMA MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 CNS LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: CNS Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C236BA812D8AEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C236BA812D8AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

